ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Precision BioSciences partners with University of Pennsylvania to develop gene editing therapies

by Ryan Cross
September 9, 2018 | APPEARED IN VOLUME 96, ISSUE 36

 

Durham, N.C.-based start-up Precision BioSciences is expanding its collaboration with the University of Pennsylvania to develop therapies based on its Arcus gene editing technology, an alternative to CRISPR gene editing. The duo’s three-year partnership will use Arcus to inactivate genes in nonhuman primates. Penn’s famous gene therapy scientist, James Wilson, recently used Arcus to inactivate a gene called PCSK9 and lower cholesterol in macaques (Nat. Biotechnol. 2018, DOI: 10.1038/nbt.4182). The pair may also develop therapies to repair or introduce genes with Arcus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment